## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($548.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. KeyBanc upgrades Thermo Fisher Scientific stock rating to Overweight with $750 target**
- Source: Investing.com | 20251208T055050 | Bullish | Relevance: 99%
-  KeyBanc has upgraded Thermo Fisher Scientific (NYSE:TMO) to Overweight with a $750 price target, citing improving macro conditions and strong execution. The firm notes normalizing biopharma spending and above-average growth in key areas like BioProduction and Research & Safety. Thermo Fisher has also recently expanded bioprocessing capabilities in Asia and issued â‚¬2.1 billion in senior notes, while Moody's and Morgan Stanley also upgraded the company's ratings.

**2. Baker Avenue Asset Management LP Boosts Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T084201 | Somewhat-Bullish | Relevance: 99%
-  Baker Avenue Asset Management LP increased its stake in Thermo Fisher Scientific Inc. by 13.3%, now holding 23,034 shares valued at $9.34 million. This comes as institutional investors collectively own about 89.23% of the company, which recently reported strong quarterly earnings exceeding estimates and announced a $5.0 billion share buyback and a $0.43 quarterly dividend. Despite some insider selling, analysts maintain a "Moderate Buy" rating for Thermo Fisher Scientific.

**3. Q4 Earnings Estimate for TMO Issued By KeyCorp**
- Source: MarketBeat | 20251209T133338 | Bullish | Relevance: 99%
-  KeyCorp analysts have issued their Q4 2025 earnings per share estimate for Thermo Fisher Scientific (NYSE: TMO) at $6.48, maintaining an "Overweight" rating and a $750.00 price target. This comes alongside other analyst updates, with a consensus "Moderate Buy" rating and an average price target of $612.95 for the company. Thermo Fisher Scientific recently reported Q3 earnings of $5.79 per share, beating consensus estimates, and announced a quarterly dividend and a $5.00 billion share repurchase program.

**4. Natixis Has $23.43 Million Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T132304 | Bullish | Relevance: 99%
- Natixis significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.6% in the second quarter, bringing its holding to 57,783 shares valued at $23.43 million. Other institutional investors also adjusted their positions in the medical research company, which recently reported strong earnings and announced a quarterly dividend of $0.43 per share. Wall Street analysts maintain a "Moderate Buy" rating for TMO, with a consensus price target of $612.95.

**5. Stockbridge Partners LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T122944 | Somewhat-Bullish | Relevance: 98%
-  Stockbridge Partners LLC reduced its Thermo Fisher Scientific Inc. (NYSE:TMO) holdings by 5.5% in Q2, as detailed in its latest SEC filing. The firm now owns 611,951 shares, making TMO its 11th largest position, accounting for 4.9% of its holdings. This comes amidst other institutional investors modifying their stakes and company insiders selling shares.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Heavy insider selling: $42M sold (14 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.3x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $215.6B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.3 |
| Current P/E | 25.2 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.6% to -1.6% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.71), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.61% (CS: 32) | Neutral |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | -3.71 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.192x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $573.81
- **Stop Loss:** $548.47 (4.4% risk)
- **Target:** $599.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 19
- **Position Value:** $10,902.39
- **Portfolio %:** 10.90%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*